ProShare Advisors
RXRX icon

ProShare Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

ProShare Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Sell
84,212
-5,581
-6% -$18.6K ﹤0.01% 1397
2026
Q1 		$276K Sell
89,793
-2,449
-3% -$9.46K ﹤0.01% 1385
2025
Q4 		$377K Buy
92,242
+14,303
+18% +$70.8K ﹤0.01% 1307
2025
Q3 		$380K Sell
77,939
-6,614
-8% -$34.7K ﹤0.01% 1269
2025
Q2 		$428K Buy
84,553
+12,300
+17% +$60.4K ﹤0.01% 1206
2025
Q1 		$382K Sell
72,253
-15,905
-18% -$116K ﹤0.01% 1246
2024
Q4 		$596K Buy
88,158
+26,847
+44% +$181K ﹤0.01% 1173
2024
Q3 		$404K Buy
61,311
+28,434
+86% +$204K ﹤0.01% 1269
2024
Q2 		$247K Sell
32,877
-8,072
-20% -$70.4K ﹤0.01% 1415
2024
Q1 		$408K Buy
40,949
+5,051
+14% +$56.2K ﹤0.01% 1210
2023
Q4 		$354K Buy
35,898
+4,829
+16% +$34.4K ﹤0.01% 1265
2023
Q3 		$238K Buy
31,069
+1,372
+5% +$13.7K ﹤0.01% 1358
2023
Q2 		$222K Buy
29,697
+895
+3% +$6.26K ﹤0.01% 1469
2023
Q1 		$192K Sell
28,802
-3,809
-12% -$30.2K ﹤0.01% 1468
2022
Q4 		$251K Buy
32,611
+3,707
+13% +$36.4K ﹤0.01% 1341
2022
Q3 		$308K Buy
28,904
+954
+3% +$9.66K ﹤0.01% 1136
2022
Q2 		$227K Sell
27,950
-10,157
-27% -$68K ﹤0.01% 1395
2022
Q1 		$272K Sell
38,107
-9,542
-20% -$101K ﹤0.01% 1692
2021
Q4 		$816K Buy
+47,649
New +$897K ﹤0.01% 1155
2021
Q3 		– Sell
-5,482
Closed -$200K – 2219
2021
Q2 		$200K Buy
+5,482
New +$162K ﹤0.01% 2144

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ProShare Advisors's RXRX Position: Q2 2026 in Review

ProShare Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 6.2% in Q2 2026, selling an estimated $18.6K and leaving 84,212 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

ProShare Advisors first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $816K in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • ProShare Advisors held 84,212 shares of Recursion Pharmaceuticals worth $309K as of Q2 2026.
  • ProShare Advisors sold 5,581 Recursion Pharmaceuticals shares in Q2 2026, an estimated $18.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1397 holding.
  • ProShare Advisors first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • ProShare Advisors's Recursion Pharmaceuticals position peaked at $816K in Q4 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.